Ilaris Infusion
Canakinumab
150mg/ml
Novartis Pharma AG
| Pack size | 1 Glass Vial (Powder) |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | CITY MEDICAL STORE |
| Retail Price | 73212.50 AED |
Available as:
Indications
Ilaris Infusion is used for:
Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Canakinumab :
Mechanism of Action
In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1@) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1@, and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1@ activation. Canakinumab is a human monoclonal anti-human IL-1@ antibody of the IgG1/? isotype. Canakinumab binds to human IL-1@ and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1a or IL-1 receptor antagonist (IL-1ra).
Note
Ilaris 150mg/ml Infusion manufactured by Novartis Pharma AG. Its generic name is Canakinumab. Ilaris is availble in United Arab Emirates.
Farmaco UAE drug index information on Ilaris Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.